Roche doubles down on Tau

Targeting beta-amyloid looks unlikely to go away as an Alzheimer’s approach any time soon, but other mechanisms are being pursued too. As Evaluate Vantage has pointed out, one of the most popular now is blocking tau, and one of the most prominent players here, Roche, just doubled down on the approach. The Swiss firm has put $120m towards UCB’s anti-tau MAb UCB0107, which so far has been studied only in volunteers and in patients with progressive supranuclear palsy (PSP).